1800 244 735

Helpline (02) 9874 9777

Mutant yeast highlights crucial CAG-reading protein

A study in yeast has highlighted a DNA-reading protein called SPT4 as possibly controlling which CAG-containing genes are active. Since Huntington’s disease is caused by a gene with a long CAG stretch, this might be important for understanding how the HD gene works.

CAG and HD

The genetic abnormality that causes Huntington’s disease is an unusually long stretch of the chemical letters C, A and G at the start of the Huntingtin gene. Huntington’s disease happens when either of a person’s two copies of the gene has 36 or more repeats.

The unusually long CAG stretch tells cells to produce a protein with more ‘glutamine’ building blocks than normal. Too many glutamines makes the protein faulty and harmful to neurons. One of the key jobs of HD researchers is to find out why this is the case.

Biologists use the letter Q to represent glutamine building blocks – so proteins with lots of glutamines in a row are called polyQ proteins.

Now, the findings of an international group of scientists, reported in the journal Cell, have highlighted the importance of a protein called SPT4 in the way cells read CAG-containing genes like huntingtin. The work has improved our understanding of how the HD gene behaves, but lots more work is needed before this could lead to a treatment for HD.

Yeast said, soonest mended

Yeast is versatile stuff. It’s well known that it’s used to make bread and beer, but you might not know it’s also useful for studying genetic diseases. Studying genetic variation is easier when you can grow thousands or millions of variants, rather than studying a much smaller number of mice or people.

The researchers, led by Tzu-Hao Cheng of National Yang-Ming University, Taiwan, decided to see if there were any strains of yeast that were better at protecting themselves from the effects of big CAG repeats in their DNA.

So, they added a new gene to the yeast cells – a gene with lots of CAGs. Using a color-changing chemical reaction, they were able to see very quickly which cells were able to cope with the long CAG stretch.

They tested 180,000 different strains of yeast. In one strain, the color change indicated that the cells had done something to overcome the effects of the abnormal polyQ protein. They found that this strain had a new mutation in another gene – the one that tells cells to make a protein called SPT4.

Transcription factors

SPT4 is what’s called a transcription factor protein – a molecular machine that directly controls which genes are turned on or off in a cell. So it makes sense that mutating SPT4’s own gene altered how much polyQ protein was produced.

SPT4 and CAG

The researchers next deliberately bred a strain of yeast with the SPT4 gene missing, to see what would happen if the cell lacked SPT4 completely. They found that these cells produced less of the PolyQ protein.

Wondering whether this meant that SPT4 was helping cells to make polyQ protein, the researchers looked closely at how the DNA-reading machinery was interacting with the DNA in the cells. They found that when SPT4 was missing, gene reading machinery was less likely to be attached to the DNA at CAG repeat stretches.

From this, they concluded that SPT4 might be responsible for steering the DNA-reading machinery to genes that contain lots of CAGs.

What about HD?

If SPT4 is involved in reading CAG repeats in yeast, does that mean it’s involved in Huntington’s disease?

To begin Cheng’s team grew neurons in a dish from an HD mouse model. Those neurons produce the mutant huntingtin protein. They used a gene silencing technique called RNAi to ‘switch off’ the SPT4 gene. In mice and humans, it’s called ‘Supt4h’. Not terribly catchy, but that’s geneticists for you.

When the Supt4h gene was switched off, the researchers found that production of mutant huntingtin was decreased – but production of ‘normal’ huntingtin was unaffected.

What does this mean for drugs?

If SPT4 (or Supt4h) is involved in controlling how much mutant huntingtin neurons produce, could its powers be harnessed to fight HD?

As we’ve reported previously, silencing the huntingtin gene is a major angle of attack for HD researchers. That means using drugs to tell cells to produce less of the huntingtin protein. Ideally, we’d be able to switch off just the mutant protein, while leaving the normal one untouched. Making and testing gene silencing drugs that do that is hard.

So anything that helps us understand how the HD gene works might come in handy when it comes to silencing the gene.

Looking further ahead, if we could mimic the effects of turning off the Supt4h gene, it might be one angle of attack for reducing levels of the mutant protein

At the moment, that’s a less appealing approach than silencing the HD gene directly, because Supt4h controls genes other than the huntingtin gene, and also has effects beyond controlling which genes are active – that might cause unwanted side effects. Right now, we don’t have drugs to controlling Supt4h, either.

So at the moment this research is probably best viewed as an interesting new insight into the workings of the HD gene – and investigating this new angle might prove useful in the long term, perhaps as a way of ‘tweaking’ or enhancing direct gene silencing techniques.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more